Cantabria Labs Launches QuaPharma as a Pharmaceutical CDMO Spin-Off
Cantabria Labs has launched QuaPharma, a contract manufacturing spin-off designed to supply both its parent company and other pharmaceutical laboratories, according to Cantabria Económica.
The new venture starts with 70 workers and aims to reach nearly 200 employees within four years.
The enterprise was established in April at the Morero industrial estate in Astillero, with operations already underway at the Cantabria Labs facility in La Concha de Villaescusa. Enrique Quintana González announced the venture on LinkedIn on September 17, stepping down as industrial and operations director of Cantabria Labs to lead the new contract development and manufacturing organization.
Quintana began working at IFC, now Cantabria Labs, 30 years ago alongside his recently deceased father. Shortly before, in 1991, the Santander-based company had passed to Juan Matji, a consultant from Mallorca who was hired to proceed with an orderly closure and who not only believed its continuation was possible but has given it an extraordinary boost over these years.
“Quienes me conocen saben que soy inquieto, que me estimulan los cambios y el vértigo de la incertidumbre,” Quintana said on LinkedIn.
The creation of the spin-off follows pandemic-era supply chain disruptions that exposed Europe’s heavy reliance on imported active pharmaceutical ingredients from Asia.
The European Union’s push to secure domestic production of critical medications supports the timing of the new venture, alongside a broader shift among European pharmaceutical companies toward regional suppliers, who are increasingly choosing community providers even though their prices do not manage to be as competitive as those offered by laboratories in India or China.
| Metric | Initial Phase | Four-Year Plan |
|---|---|---|
| Workforce | 70 operarios | ~200 personas |
| Investment | 15–20 million euros | — |
| Target Revenue | — | ~50 million euros |
QuaPharma plans to invest between 15 million and 20 million euros in the Morero facilities, which occupy a former Conservas Islas Cíes plant, according to Cantabria Económica. Its four-year business plan targets an annual turnover of approximately 50 million euros, backed by a CDMO model that integrates pharmaceutical development, manufacturing, and regulatory services.
Its activity is going to be complementary to that of Moehs, whose plant in Requejada, Polanco, is focused on the manufacturing of the molecules that laboratories use as active ingredients for their products.
In 1989, Cantabria Labs avoided closure when a consultant was hired to liquidate the business, but instead saw potential in the failing Cantabria laboratory. Partnering with the Quintana family, the new leadership chose to pivot the enterprise away from its original trajectory.
By optimizing resources and specializing the company in dermatology, this strategy successfully transformed the struggling organization into a thriving pharmaceutical group capable of launching a contract development and manufacturing spin-off decades later.
The company enters the market with GMP certifications meeting regulatory standards across Europe, America, Asia, and Africa. Contract manufacturing for semi-solids alone generates 21,700 million dollars globally each year, growing at an annual rate of 11%, while the broader pharmaceutical contract market reaches approximately 185,000 million dollars, Cantabria Económica noted.